Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Started Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: Study
FRIDAY, June 26, 2020 -- Early and intensive treatment with methotrexate and prednisone can ease fatigue in people with rheumatoid arthritis (RA), according to a new study. RA causes chronically inflamed joints and that inflammation can lead to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 26, 2020 Category: General Medicine Source Type: news

COVID - 19 Hospitalization Up With Prednisone in Rheumatic Disease
No correlation seen for DMARD alone or in combination with biologics, Janus Kinase inhibitors, NSAIDs (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news

COVID-19 Hospitalization Up With Prednisone in Rheumatic Disease
TUESDAY, June 23, 2020 -- For patients with rheumatic disease with COVID-19, glucocorticoids are associated with increased odds of hospitalization, according to a study published in the July issue of the Annals of Rheumatic Diseases. Milena... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2020 Category: Pharmaceuticals Source Type: news

What Does Prednisone Do to Your Body?
Title: What Does Prednisone Do to Your Body?Category: MedicationsCreated: 6/23/2020 12:00:00 AMLast Editorial Review: 6/23/2020 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 23, 2020 Category: Drugs & Pharmacology Source Type: news

Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumoursBasel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCR...
Source: Roche Media News - June 19, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
Basel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN loss. In this patient group, ipatasertib in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to current standard of care (abiraterone and prednisone/prednisolone) plus placebo. The other co-primary endpoint of rPFS in the overal...
Source: Roche Investor Update - June 19, 2020 Category: Pharmaceuticals Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

TNF Inhibitors May Dampen COVID-19 Severity TNF Inhibitors May Dampen COVID-19 Severity
Patients on a TNF inhibitor when contracting COVID-19 were less likely to require hospitalization. Conversely, patients on ≥ 10 mg of prednisone daily when infected were more likely to be hospitalized.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - May 21, 2020 Category: Rheumatology Tags: Rheumatology News Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Anifrolumab Benefits Seen in Second Lupus RCT Analysis Anifrolumab Benefits Seen in Second Lupus RCT Analysis
The monoclonal anifrolumab improved BICLA responses, reduced use of prednisone, and improved skin disease in patients with SLE, particularly those with high type 1 interferon gene signatures.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 23, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news

University of Cincinnati finds new option for liver transplant patients
(University of Cincinnati) Budesonide, a drug commonly used to treat Crohn's Disease, may offer fewer side effects and work at least as well as prednisone as an anti-organ rejection medication in liver transplant patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2019 Category: International Medicine & Public Health Source Type: news

Study Finds Those With Asthma Should Avoid High-Dose Steroids
BOSTON (CBS)- A warning for people with asthma.  A new study finds some asthmatics are taking harmful doses of steroids that could be putting their health at risk. Oral steroids, like prednisone, reduce inflammation and are often used to ease the breathing of patients in the throes of an asthma attack.  But prolonged or excessive doses can put patients at higher risk for diabetes, osteoporosis and hormonal abnormalities. Researchers in the Netherlands studied more than two thousand patients with severe asthma who were on high doses of inhaled steroids and found that almost a third of them were also taking harmful...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 2, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Asthma Dr. Mallika Marshall Health Watch oral steroids Source Type: news

Can Metformin Improve Outcomes When Added to Chemotherapy in Prostate Cancer?
The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

‘More Is Not Better’ in Metastatic Castration-Resistant Prostate Cancer
This study compared combination therapy with enzalutamide, abiraterone, and prednisone vs enzalutamide alone in men with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

Medical News Today: Is it safe to drink alcohol while taking prednisone?
Whether a person can drink alcohol while taking prednisone depends on a range of factors, including the length of the treatment, the dosage, and how much alcohol they drink. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 7, 2019 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news

Final LATITUDE Results Confirm Previous Findings for High-Risk Prostate Cancer
Final results of LATITUDE confirm the beneft of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

prednisone (Prednisone Intensol, Rayos) Corticosteroid
Title: prednisone (Prednisone Intensol, Rayos) CorticosteroidCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 2/27/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - February 27, 2019 Category: Rheumatology Source Type: news

New research insights hold promise for kids with DMD
(Children's National Health System) Prednisone, the current standard of care used to treat kids with Duchenne muscular dystrophy (DMD), reduces chronic inflammation but has harsh side effects. Eplerenone, a heart failure drug, is used in older patients to treat cardiomyopathy, a leading cause of mortality for people with DMD. A new medicine under development appears to combine the beneficial effects of these drugs for the heart and muscle while also showing improved safety in experimental models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2019 Category: International Medicine & Public Health Source Type: news

Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis
Thymectomy plus prednisone improves outcomes in patients with non-thymomatous myasthenia gravis (MG), compared with prednisone alone, according to results from the two-year extension of the MGTX randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 6, 2019 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Thymectomy & #43; PDN Beneficial for Non-Thymomatous Myasthenia Gravis
WEDNESDAY, Jan. 30, 2019 -- For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at five years, according to a study published online Jan. 25 in The Lancet Neurology. Gil I. Wolfe,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2019 Category: Pharmaceuticals Source Type: news

ASH: A & #43;CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 -- For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2018 Category: Drugs & Pharmacology Source Type: news

Corticosteroids are linked to an increased risk of irregular heart beat
(Natural News) Taking corticosteroids, such as prednisone, can increase your risk of suffering from irregular heartbeats, making you more likely to suffer from a heart condition, according to a study published in the Archives of Internal Medicine. Corticosteroids are naturally occurring hormones with a wide array of functions, including managing your stress response and regulating... (Source: NaturalNews.com)
Source: NaturalNews.com - November 16, 2018 Category: Consumer Health News Source Type: news

Prednisone Cuts Risk of Dangerous Immune-System Rebound During HIV-TB Treatment Prednisone Cuts Risk of Dangerous Immune-System Rebound During HIV-TB Treatment
Giving low-dose prednisone soon after initiation of HIV therapy to people who are both infected with tuberculosis and have very low CD4 counts can prevent their immune system from dangerously rebounding against the TB infection, doctors report.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 16, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Medical News Today: What is the difference between methylprednisolone and prednisone?
Methylprednisolone and prednisone are medications that can treat certain health conditions, such as rheumatoid arthritis, by reducing inflammation in the body. Learn about the differences between these corticosteroids here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 31, 2018 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news

Investigational steroid mirrors prednisone's benefits while taming its side effects
(Children's National Health System) A head-to-head trial comparing the decades-old steroid, prednisone, and a promising new steroid, vamorolone, finds both act on the same key set of genetic pathways involved in controlling inflammation, indicates a new study led by Children's National Health System researchers. However, the study suggests the new investigational steroid doesn't activate several additional pathways involved in prednisone's bevy of undesirable side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2018 Category: International Medicine & Public Health Source Type: news

Medical News Today: How to deal with prednisone withdrawal
Prednisone is a drug that contains synthetic cortisol. When a person takes prednisone, the body stops making enough cortisol on its own. This can lead to withdrawal symptoms when the person stops taking the medication or reduces their dose too quickly. Here, learn more about the symptoms and how to prevent them. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 20, 2018 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news

Deadly Respiratory Distress Mimic
Medic 534, staffed by a paramedic and EMT, is dispatched to a nursing home for a 78-year-old female in respiratory distress. On arrival, the crew finds the patient in a chair accompanied by two nurses and the administrator on call. The patient is in obvious distress showing fatigue and an increased work of breathing. She is alert to voice, but diaphoretic, lethargic, and unable to speak due to rapid, shallow breathing. A nurse is administering a nebulizer containing 3 mL of albuterol sulfate/ipratropium. A second nurse states that the patient has been in increasing distress for the last 45 minutes. The nurse also says that...
Source: JEMS Patient Care - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Patient Care Source Type: news

Deadly Respiratory Distress Mimic
Conclusion It’s important for prehospital providers to be able to differentiate metabolic disturbances in the setting of respiratory distress and not be fooled into thinking tachypnea always has a respiratory cause. The physical exam and adjuncts such as end-tidal capnography can assist in the prehospital diagnosis. A COPD exacerbation generally presents as diminished lung sounds, wheezing on exhalation, and a prolonged expiratory phase. Here, a patient will attempt to compensate for the inflammation and mucus accumulation associated with the destruction and narrowing of peripheral airways and a subsequent lack of av...
Source: JEMS Special Topics - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Exclusive Articles Patient Care Source Type: news

Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Adjuvant Docetaxel Fails in Higher-Risk Prostate Ca
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

No DFS Benefit: Adjuvant Docetaxel in Higher-Risk Prostate Ca
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

ASCO: Overall Survival Up for African - American Men With mCRPC
Improved survival versus Caucasian men treated with docetaxel/prednisone, DP - containing regimen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 7, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news

ASCO: Overall Survival Up for African-American Men With mCRPC
THURSDAY, June 7, 2018 -- Overall survival is increased for African-American men with metastatic castration resistant prostate cancer (mCRPC) versus Caucasian men treated with docetaxel/prednisone (DP) or a DP-containing regimen, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 7, 2018 Category: Pharmaceuticals Source Type: news

Medical News Today: How does prednisone treat an asthma flare-up?
Prednisone is a steroid that can be used as part of a person's treatment after they have a significant asthma attack. In this article, we examine the effect the drug has on inflammation in the airways to help improve breathing, the possible side effects it can cause, and other medications that may be used alongside it. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 25, 2018 Category: Consumer Health News Tags: Asthma Source Type: news

UAB-led study shows promise for bone density drug
An alternative treatment for people taking glucocorticoids shows promise through a UAB-led study.   Long-term use of these drugs, which includes prednisone, causes osteoporosis, which results in a yearly bone fracture rate of 5 percent.  A UAB-led international study published in “The Lancet Diabetes& Endocrinology ” medical journal, and headed by Kenneth Saag, professor of medicine at UAB, indicates alternative drugs can be effective. The study was funded by Amgen which markets denosumab… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 30, 2018 Category: Biotechnology Authors: Tyler Patchen Source Type: news

UAB-led study shows drug effectiveness in reducing glucocorticoid-induced bone loss
(University of Alabama at Birmingham) About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce glucocorticoid-induced bone loss, causing an estimated yearly bone fracture rate of 5 percent. An alternative treatment option to the standard treatment now appears promising, according to an international study. Researchers compared the monoclonal antibody denosumab against a standard bisphosphonate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2018 Category: International Medicine & Public Health Source Type: news

No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone
Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 18, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Prostate Cancer Source Type: news

ADT Alone Prevails in High-Risk Prostate Cancer (CME/CE)
(MedPage Today) -- No survival bump with postoperative mitoxantrone, prednisone (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 10, 2018 Category: Endocrinology Source Type: news

Abiraterone, Docetaxel Best With ADT for Metastatic Prostate Cancer
Abiraterone plus prednisolone/prednisone, or docetaxel, combined with ADT may be the most effective therapies for metastatic hormone-naive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

Which Combo for Newly Diagnosed Metastatic Prostate Cancer? Which Combo for Newly Diagnosed Metastatic Prostate Cancer?
The combination of abiraterone, prednisone, and castration proves to be a beneficial option for metastatic prostate cancer.Medscape Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2018 Category: Consumer Health News Tags: Urology Commentary Source Type: news

Prednisone vs. Budesonide
Title: Prednisone vs. BudesonideCategory: MedicationsCreated: 2/23/2018 12:00:00 AMLast Editorial Review: 2/23/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 23, 2018 Category: Drugs & Pharmacology Source Type: news

Zytiga (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
HORSHAM, PA, Feburary 8, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Zytiga (abiraterone acetate) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 8, 2018 Category: Drugs & Pharmacology Source Type: news

ZYTIGA(R) (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
New indication for ZYTIGA® in combination with prednisone provides treatment option for patients with metastatic high-risk castration-sensitive prostate cancer Findings from pivotal Phase 3 LATITUDE clinical trial data demonstrated statistically sig... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, ZYTIGA, abiraterone, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2018 Category: Pharmaceuticals Source Type: news

ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 8, 2018 Category: Pharmaceuticals Source Type: news

QOL Data Reassuring for Abiraterone in Prostate Cancer QOL Data Reassuring for Abiraterone in Prostate Cancer
A new analysis of the LATITUDE trial shows that addition of abiraterone plus prednisone to ADT improves not only survival but also pain, fatigue, and quality of life (QOL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Phase 3 ALCYONE data showed DARZALEX in combination with bortezomib, melphalan and prednisone meaningfully improved progression-free survival and response rates Data featured as late-breaker at ASH 2017 (Abstract #LBA-4) and published in the New England... Biopharmaceuticals, Oncology Janssen Biotech, DARZALEX, daratumumab, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 12, 2017 Category: Pharmaceuticals Source Type: news